Bionomics sells up to focus on key drug
Biotechnology drug developer Bionomics has sold its French subsidiaries to focus on commercialising its lead drug candidate to treat post traumatic stress disorder. The company sold Neurofit and Prestwick Chemical which carry out contract research to Domain Therapeutics. Consideration for the sale was $3 million which is the amount of inter-company debt owed by Bionomics…
Details